

We claim:

1. A solid or semisolid preparation of paroxetine or one of its  
5 physiologically acceptable salts in the form of a molecular  
dispersion of paroxetine in a pharmaceutically acceptable  
matrix material which comprises a completely synthetic  
polymer having a glass transition temperature of >90°C.

10 2. A preparation as claimed in claim 1, comprising paroxetine  
hydrochloride.

15 Sub A1 → 3. A preparation as claimed in either of claims 1 or 2 having an  
active ingredient release of at least 80% after 30 min.

4. A process for producing a preparation as claimed in any of  
claims 1 to 3, which comprises the paroxetine or one of its  
salts and the matrix material being mixed to give a  
homogeneous melt in an extruder and subsequently being  
20 shaped.

5. A process as claimed in claim 4 for producing a paroxetine  
hydrochloride preparation, wherein paroxetine is processed  
with ammonium chloride and the matrix materials to give a  
25 homogeneous melt.

6. A process as claimed in claim 5, wherein amorphous paroxetine  
or one of its physiologically acceptable salts is employed.

30

35

40

45